This website uses cookies to ensure you get the best experience on our website. Learn more

Johnson and Johnson COVID Vaccine from Janssen

x
  • Johnson and Johnson COVID Vaccine from Janssen

    5:58

    Johnson and Johnson COVID Vaccine from Janssen

    The NEW COVID Vaccine from Johnson and Johnson has arrived. It has 2 BIG advantages compared to the mRNA vaccines. One, it's a single dose. Two, it does not require super-cold temperatures. This will make it way easier to mass vaccinate.

    The study was called the ENSEMBLE Trial, a randomized, double-blind, placebo-controlled phase 3 study, meaning that thousands of patients are enrolled and assess the vaccine's safety and efficacy. Unlike the Pfizer/BioNTech and Moderna vaccines, mRNA vaccines, the Johnson and Johnson vaccine is a recombinant vector. In this case, it takes another virus, an adenovirus, to modify that virus to cause infection in the body. However, that virus can still serve as a delivery messenger to deliver the genetic code for some SARS-CoV-2 viruses. Specifically, the genetic code that codes for the spike protein of the virus. One of the enormous advantages of this Johnson and Johnson vaccine is that it is a single-dose vaccine. The other significant advantage of this Johnson and Johnson vaccine is that it can remain stable for two years at -20°C (-4°F), at least three months of which can be at temperatures of 2-8°C (36°F–46°F).

    Why is this significant?
    Because that means, unlike the mRNA vaccines, regular refrigeration will suffice for mass distribution.

    But how effective is this Johnson and Johnson vaccine?
    The ENSEMBLE trial enrolled over 43,000 participants ages 18 years and older from the United States, Latin America, and South Africa. About 1% of patients enrolled in the study developed covid. It was 66% effective at preventing moderate and severe Covid by day 28 after vaccination among all participants, including those who lived in regions with the new emerging viral variant such as the P1 variant in Brazil and B.1.351 variant in South Africa. Protection against SARS-CoV-2 was most significant in the United States at 72% and worst in South Africa at 57%. About 95% of those in the trial who developed covid in South Africa were found to have been infected with the B.1.351 variant.

    That B.1.351 variant has been found to have some resistance to antibodies generated due to previous infections and other vaccines. Within the B.1.351 variant, the E484K mutation has appeared sporadically in multiple samples for months. Still, until recently, it didn't appear to offer the virus an advantage in populations with no preexisting immunity. But it's a different story in places like South Africa, where many people had been previously infected. In South Africa, there has been a very high reinfection rate to the point where the previous infection does not seem to protect you.

    But how protective is the Johnson and Johnson vaccine against SEVERE disease?
    It was 85% effective in all regions by day 28, and there was no severe covid after day 49.

    Does this mean the Johnson and Johnson vaccine is 100% effective at preventing severe covid by day 49?
    We will only know for sure with time and once the entire data from the study becomes available. It’s also worth noting that no one who received the Johnson and Johnson vaccine was hospitalized with covid or died with 28 days of getting this covid vaccine.
    Preventing severe disease in a high percentage of people will significantly alleviate this virus's devastation.

    How safe is the Johnson and Johnson vaccine?
    Serious adverse events, meaning side effects, were rare, with more participants in the placebo group reported adverse events than the vaccine group. This implies that some of the adverse events reported by patients in the placebo arm may have contracting actual COVID disease. The overall rates of fever were 9%. The percentage of people who developed high fevers, meaning Grade 3 fevers, defined as greater than 39°C or 102.1°F) 0.2%.

    So, Johnson and Johnson vaccine will soon be filing for Emergency Use Authorization in the United States. This comes in the nick of time because we have to vaccinate as quickly as possible before the new variants become the dominant strain. Because if that happens, the consequences could entail ineffective antibody protection, which means we would take a giant step backward to get this pandemic under control.

    Doctor Mike Hansen, MD
    Internal Medicine | Pulmonary Disease | Critical Care Medicine
    Doctor Hansen's Courses:
    Contact and Social Media Links:

    #vaccine​ #covid

  • x
  • Johnson & Johnson COVID-19 Vaccine: Effectiveness, Side Effects and Differences Between Vaccines

    2:45

    Dr. Dean Blumberg, Chief of Pediatric Infectious Diseases at UC Davis Children's Hospital, explains how the new Johnson and Johnson COVID-19 vaccine works and answers common questions, including why it's different from other coronavirus vaccines, how side effects compare to Pfizer and Moderna vaccines and more.

    For the latest information and resources on COVID-19, visit
    See the latest news from UC Davis Health:

    0:00 How is the Johnson & Johnson vaccine different?
    0:25 Why is it easier to distribute?
    1:00 Is it as effective as other COVID vaccines?
    1:44 Are the side effects different?
    2:01 Why is it important to have another vaccine available?

    #JohnsonandJohnson #covid19 #vaccine #coronavirus

  • x
  • Comparing Johnson & Johnson Janssen Covid-19 Vaccine to Pfizer and Moderna

    2:19

    MCW associate professor Dr. Ben Weston shares his knowledge on the benefits, development technology, and the safety and efficacy of the Johnson & Johnson/Janssen COVID-19 vaccine.

    Find more information and resources regarding COVID-19 vaccines here:

    To read up-to-date and trustworthy news on the COVID-19 pandemic, visit:

    0:00 – Johnson & Johnson/Janssen Vaccine Overview and Benefits

    0:37 – Johnson & Johnson/Janssen Vaccine Development Technology

    1:23 – Johnson & Johnson/Janssen Vaccine Safety

  • Coronavirus Update 121: Johnson and Johnson Vaccine - Efficacy and Safety vs. Pfizer & Moderna

    11:49

    Professor Roger Seheult, MD explains the Johnson and Johnson / Janssen Pharmaceuticals vaccine candidate for COVID 19. Dr. Seheult illustrates how the Johnson & Johnson adenovirus vaccine works, the efficacy/safety (based on preliminary data), and how the vaccine compares to the Moderna vaccine and the Pfizer BioNTech vaccine. (This video was recorded on February 4, 2021).

    Roger Seheult, MD is the co-founder and lead professor at
    He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine.

    Interviewer: Kyle Allred, Physician Assistant, Producer / Co-Founder of MedCram.com

    LINKS / REFERENCES:

    A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (NIH) |

    Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial (Johnson & Johnson) |

    J&J one-dose Covid vaccine is 66% effective, a weapon but not a knockout punch (STAT) |

    One-shot COVID-19 vaccine is effective against severe disease (ScienceNews) |

    UK COVID Symptom Study |

    Doctor Explains The PREVENTION & TREATMENT For The Coronavirus | Roger Seheult & Lewis Howes (Lewis Howes YouTube Channel) |


    THE MEDCRAM WEBSITE:

    Visit us for videos on over 60 medical topics and CME / CEs for medical professionals:


    SUBSCRIBE TO THE MEDCRAM YOUTUBE CHANNEL:


    Get notified of new videos by hitting the bell icon:


    RECENT PREVIOUS COVID-19 UPDATES:

    Please visit MedCram.com for the full series:
    - Coronavirus Update 120: Anticoagulants (Blood Thinners) Improve Hospital Outcomes (Full Dose)
    - Coronavirus Update 119: Pfizer BioNTech COVID Vaccine (Clinical Considerations)
    - Vitamin D and COVID 19: The Evidence for Prevention and Treatment of Coronavirus (SARS CoV 2)
    - Coronavirus Update 118: AstraZeneca DNA COVID 19 Vaccine Explained (vs. Pfizer / BioNTech, Moderna)
    - Coronavirus Update 117: Moderna vs. Pfizer COVID 19 Vaccine (mRNA vaccines)
    - Coronavirus Update 116: Pfizer COVID 19 Vaccine Explained (Biontech)
    - Coronavirus Update 115: Convalescent Plasma vs Monoclonal Antibodies for COVID 19 Treatment
    - Coronavirus Update 114: COVID 19 Death Rate Drops; NAC (N acetylcysteine) Data
    - Coronavirus Update 113: Remdesivir May Not Work for COVID 19
    - Coronavirus Update 112: Linoleic Acid; Vaccines; UK COVID 19 Data
    - Coronavirus Update 111: Masks; New Vitamin D Data and COVID 19; NAC
    - Coronavirus Pandemic Update 110: Trump's Risk Factors and COVID-19 Prognosis; Interferon
    - Coronavirus Pandemic Update 109: New Data From Europe As COVID 19 Infections Rise
    - Coronavirus Pandemic Update 108: High Risk COVID 19 Behaviors; Cases Rise in Europe
    - Coronavirus Pandemic Update 107: Monoclonal Antibodies for COVID 19 Treatment and Prevention?

    All coronavirus updates are at ad-free MedCram.com (including this video on the Johnson and Johnson Vaccine).
    We offer over 60 medical topics (ECG Interpretation, DKA, influenza, measles, mechanical ventilation, etc.) on our website.


    MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS:

    MedCram offers group discounts for students and a variety of medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested.


    MEDIA CONTACT:

    Media Contact: customers@medcram.com
    Media contact info:

    Video Produced by Kyle Allred

    FOLLOW US ON SOCIAL MEDIA:






    DISCLAIMER:

    MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor.
    #COVID19 #SARSCoV2 #Coronavirus

  • x
  • Johnson & Johnson: Covid vaccine booster increases protection to 94%

    5:14

    CNBC's Meg Tirrell reports on Johnson & Johnson's coronavirus vaccine and the study results behind a second dose of its Covid vaccine. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Johnson & Johnson said Tuesday its Covid-19 booster shot is 94% effective when administered two months after the first dose in the United States. It also said the booster increases antibody levels by four to six times compared with one shot alone.

    A J&J booster dose given six months out from the first shot appears to be potentially even more protective against Covid, the company said, generating antibodies twelvefold higher four weeks after the boost, regardless of age.

    When given as a booster, the vaccine remained well tolerated, with side effects generally consistent with those seen after the initial dose, according to J&J.

    “We now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly,” J&J chief scientific officer Dr. Paul Stoffels said in a statement.

    The new data, provided in a press release, helps J&J make a case to the Food and Drug Administration to authorize a booster shot to some 14.8 million Americans who have received the company’s single-dose vaccine.

    The Biden administration announced plans last month to roll out booster shots for people who received the Moderna and Pfizer vaccines. An FDA advisory committee on Friday unanimously recommended Pfizer booster shots to people age 65 and older and other vulnerable Americans. A final decision from the agency is expected any day now.

    U.S. health officials said they needed more data on the J&J vaccine before they can recommend boosters of those shots.

    The 94% efficacy rate for the J&J booster shot is for the U.S., the company said. Globally, a booster shot given about two months after the first dose is 75% effective against symptomatic infection, according to the company. It also demonstrated 100% effectiveness against severe and critical disease, it said.

    The company also released data from a real-world study that found a single dose of its vaccine provided strong and long-lasting protection against Covid-related hospitalizations, demonstrating 81% effectiveness after several months.

    The new data on a single dose will help the “critical” need “to prioritize protecting as many people as possible against hospitalization and death given the continued spread of COVID-19 and rapidly emerging variants,” the company said.

    “A single-shot COVID-19 vaccine that is easy to use, distribute and administer that provides strong and long-lasting protection is crucial to vaccinating the global population,” Stoffels said.
    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • Mayo Clinic Insights: How the the Johnson & Johnson COVID-19 vaccine works

    4:01

    Mayo Clinic Insights: Dr. Swift discusses what an adenovirus is and how the Johnson & Johnson COVID-19 vaccine works. For more up to date information about COVID-19, visit

  • x
  • Coronavirus: Does the Johnson and Johnson Vaccine Need a Booster for Delta Variant?

    2:12

    The delta variant is not only raising concerns for the unvaccinated, but also for people who got the Johnson and Johnson vaccine. Damian Trujillo reports.

    Stay connected:
    Follow us on Twitter:
    Like us on Facebook:
    Follow us on Instagram:
    Add us on Snapchat @NBCBayArea

    Catch up on all the day's news:

    Download our app:
    On iOS:
    On Android:

  • J&J says data supports boosting single-shot Covid-19 vaccine

    4:06

    CNBC's Meg Tirrell reports on new research from Johnson & Johnson supporting a booster to its Covid vaccine. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Johnson & Johnson said Wednesday a booster shot of its Covid-19 vaccine generated a promising immune response in early stage clinical trials – though the information provided by the company in a press release was light on some details.

    J&J’s vaccine requires only one dose and recipients are considered fully vaccinated two weeks after receiving the shot. The company said Wednesday that J&J recipients who received a booster dose of the shot generated virus-fighting antibodies “nine-fold higher” than those seen four weeks after a single dose.

    Increases in antibody responses were observed in vaccine trial participants between ages 18 and 55, the company said, and in those 65 years and older who received a lower dosage of the booster shot.

    The results are based on two Phase 1/2 studies, according to the company.

    “We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months,” Dr. Mathai Mammen, head of research and development at J&J’s Janssen vaccine arm, said in a statement.

    “With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” he added.

    While the new data is promising, the company’s press release made no mention of the booster shots’ potential impact on the coronavirus delta variant or on safety.

    When asked about data on delta, J&J referred CNBC to a report in July that showed a single dose of the vaccine generated a promising immune response to the variant.

    It also raises questions about why J&J recipients need booster shots – especially after the July report showed that a single shot of its vaccine provides immunity that lasts at least eight months and appears to deliver adequate protection against the fast-spreading delta variant.

    To be sure, the Centers for Disease Control and Prevention has said J&J recipients will probably need a booster dose but added it doesn’t have enough data right now to support a formal recommendation.

    The company said Wednesday it is engaging with the Food and Drug Administration and other health authorities regarding booster shots.

    The new data comes less than a week after J&J announced that Alex Gorsky was stepping down as CEO. Gorsky, 61, who was chairman and CEO for nine years, will become executive chairman.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • Johnson & Johnson’s Janssen COVID-19 Vaccine Overview w/ Dr. Turabelidze, MO State Epidemiologist

    27:35

    For more health information visit health.mo.gov
    For news about the State of Missouri visit mo.gov

  • x
  • Comparing Three Vaccines - Moderna, Pfizer, and Janssen

    14:49

    Please read and agree to the disclaimer before watching this video.
    . Comparing Three Vaccines - Moderna, Pfizer, and Janssen (J&J)

    Here is a comparative view of the efficacy and side effects of Moderna, Pfizer, and Johnson and Johnson vaccines as reported in their trial results in the FDA reports.

    This discussion does not include the efficacy and side effects from the vaccination campaigns.

    Buy me a coffee :-)
    Become my patron:
    Looking to support my educational work? Donate here:

    #drbeen #koolbeens #COVID ...

    Disclaimer:
    This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
    Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional. ...
    Disclaimer:
    This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
    Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

  • New Data Released On Effectiveness Of Johnson & Johnson Vaccine

    2:45

    After Monday’s potentially game-changing announcement from Pfizer on its vaccine for kids 5 to 11, new data is just out about the effectiveness of the Johnson & Johnson vaccine and how it improves with a booster shot. NBC’s Stephanie Gosk reports for TODAY.

    » Watch TODAY All Day:
    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:
    Follow TODAY on Pinterest:

    New Data Released On Effectiveness Of Johnson & Johnson Vaccine

  • Johnson & Johnson single shot Janssen vaccine shown to work | ITV News

    2:32

    Johnson & Johnson's one-dose coronavirus vaccine - which the UK has ordered 30 million doses of - has been shown to protect against Covid-19, but not as well as some two-shot rivals, trials have shown.

    The single-shot Janssen vaccine was found to be 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms.

    • Subscribe to ITV News on YouTube:
    • Get breaking news and more stories at

    Follow ITV News on Facebook:
    Follow ITV News on Twitter:
    Follow ITV News on Instagram:

  • CDC raises new concerns over Johnson & Johnson vaccine

    1:28

    CNBC's Meg Tirrell reports on CDC concerns over a neurological disorder associated with the Johnson & Johnson vaccine, and whether Covid-19 booster shots will be needed. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    The Food and Drug Administration is expected to announce a new warning for Johnson & Johnson’s Covid-19 vaccine, saying the shot has been linked to a serious, but rare, autoimmune disorder, The Washington Post reported Monday, citing four unnamed sources.

    About 100 preliminary reports of Guillain-Barre syndrome have been detected after 12.8 million doses of the J&J vaccine were administered, the Centers for Disease Control and Prevention said in a statement to NBC News. Guillain-Barre is a rare neurological disorder in which the body’s immune system mistakenly attacks part of the nervous system.

    It is estimated to affect about one person in 100,000 each year, and most people eventually recover from the disorder, according to the National Institute of Neurological Disorders and Stroke.

    The cases reported after receiving the J&J shot largely occurred about two weeks after vaccination and mostly in males, many aged 50 years and older, according to the CDC. Available data do not show a similar pattern with Pfizer’s or Moderna’s vaccine, the agency said.

    U.S. regulators are expected to emphasize that the J&J vaccine is safe and that its benefits clearly outweigh the potential risks, the Post reported, citing people familiar with the situation.

    The FDA did not immediately respond to CNBC’s request for comment.

    “Reports of GBS after receipt of the J&J/Janssen COVID-19 Vaccine in the Vaccine Adverse Event Reporting System (VAERS) are rare, but do likely indicate a small possible risk of this side effect following this vaccine,” the CDC said in the statement to NBC News.

    In a statement Monday, J&J said it has been in discussions with the FDA and other regulators about the disorder.

    “The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree,” the company said. “We strongly support raising awareness of the signs and symptoms of rare events to ensure they can be quickly identified and effectively treated.”

    The anticipated new warning is just the latest setback for J&J, which has suffered from production problems of its vaccine as well as public concerns about a rare, potentially life-threatening, blood clotting disorder linked to its shots.

    After its authorization in late February, the vaccine was touted as a blessing since it could be stored at refrigerator temperatures for months and takes just one dose — unlike Pfizer’s and Moderna’s, which require more complicated transportation methods and are two doses.

    More than 12 million of the J&J shots have been administered in the U.S., according to data compiled by the CDC.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • Fauci Says Johnson & Johnson Covid Vaccine Effective In Preventing Severe Disease | NBC News NOW

    3:44

    Dr. Anthony Fauci touts the success of the Johnson & Johnson Covid-19 vaccine in an interview with the New York Press Club.
    » Subscribe to NBC News:
    » Watch more NBC video:

    NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows.

    Connect with NBC News Online!
    NBC News App:
    Breaking News Alerts:
    Visit NBCNews.Com:
    Find NBC News on Facebook:
    Follow NBC News on Twitter:
    Follow NBC News on Instagram:

    #CovidVaccine #Covid19 #NBCNews

    Fauci Says Johnson & Johnson Covid Vaccine Effective In Preventing Severe Disease | NBC News NOW

  • J&J vaccine holds up well against delta Covid variant

    2:27

    CNBC's Meg Tirrell reports on new information that shows the J&J vaccine is effective in protecting against the delta Covid variant.

  • If You Received the J&J Vaccine, What Symptoms Should You Look Out For? | TODAY

    3:37

    NBC News medical correspondent Dr. John Torres joins Weekend TODAY to answer viewer questions surround the Pfizer, Moderna and Johnson & Johnson COVID-19 vaccines. He notes that the reports of blood clots associated with the J&J shot are one in a million, and all three vaccines are “very safe and very effective.”» Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:

    If You Received the J&J Vaccine, What Symptoms Should You Look Out For? | TODAY

  • The COVID-19 Vaccines from Johnson & Johnson and AstraZeneca: Whats in Them and How Do They Work?

    11:20

    Learn about the composition and delivery mechanism for the new classes of COVID-19 vaccines based on adenovirus from Johnson & Johnson and AstraZeneca with Dr. Jonathan Genzen, COO of ARUP Laboratories and an Associate Professor at the University of Utah School of Medicine.

  • Comparing Johnson & Johnson Vaccine to Pfizer And Moderna | NBC News NOW

    3:27

    NBC News’ Erika Edwards compares and contrasts the Johnson & Johnson vaccine to those of Pfizer and Moderna, addressing concerns about efficacy rate and ingredients.
    » Subscribe to NBC News:
    » Watch more NBC video:

    NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows.

    Connect with NBC News Online!
    NBC News App:
    Breaking News Alerts:
    Visit NBCNews.Com:
    Find NBC News on Facebook:
    Follow NBC News on Twitter:
    Follow NBC News on Instagram:

    #Vaccine #FactCheck #NBCNews

    Johnson & Johnson Vaccine Fact-Check: Efficacy, Contents And Side Effects | NBC News NOW

  • Mayo Clinic Insights: What you should know about the Johnson & Johnson COVID-19 vaccine

    3:16

    Mayo Clinic Insights: Dr. Swift discusses what you need to know about the new Johnson & Johnson COVID-19 vaccine. For more up to date information about COVID-19, visit

  • FDA Issues New Warning For J&J Vaccine Over Rare Side Effect

    1:55

    Among the 12.8 million recipients of Johnson & Johnson’s Covid vaccine, the CDC now says federal officials have identified about 100 suspected cases of Guillain-Barré syndrome, a neurological disorder in which the body’s immune system damages nerve cells. Most people who contract Guillain-Barré recover. 
    » Subscribe to NBC News:
    » Watch more NBC video:

    NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows.

    Connect with NBC News Online!
    NBC News App:
    Breaking News Alerts:
    Visit NBCNews.Com:
    Find NBC News on Facebook:
    Follow NBC News on Twitter:
    Follow NBC News on Instagram:

    #NightlyNews #Vaccine #Coronavirus

  • x
  • Johnson & Johnson Says Vaccine Effective Against Delta Variant

    1:48

    Johnson & Johnson says their own study proves its Covid-19 vaccine is effective against the delta variant, which now accounts for a quarter of all new cases. » Subscribe to NBC News:
    » Watch more NBC video:

    NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows.


    Connect with NBC News Online!
    NBC News App:
    Breaking News Alerts:
    Visit NBCNews.Com:
    Find NBC News on Facebook:
    Follow NBC News on Twitter:
    Follow NBC News on Instagram:


    #Vaccines #Delta #J&J

    Johnson & Johnson Says Vaccine Effective Against Delta Variant

  • Johnson & Johnson Vaccine Side Effect: Could Cause Neurological Disorder Including Paralysis

    3:26

    According to the US regulator, FDA, Johnson & Johnson's Covid-19 vaccine has been linked to a rare neurological disorder. Guillain-Barre syndrome has been found in a few cases among the millions of vaccine recipients. Guillain-Barre syndrome is a rare neurological disorder in which the Immune system attacks nerves. Watch the video to know more.

    #VaccineSideEffects #JohnsonVaccine #CovidVaccine

    Crux is your daily dose of the big, viral and relevant news in a few minutes. It’s your ultimate guide to staying informed on the latest in politics, international relations, sports, entertainment and social media

    Follow CRUX on Instagram (@crux.india):
    Follow CRUX on Facebook:
    #GetCloserToTheNews with latest headlines on politics, sports and entertainment on news18.com

    Also watch:
    Crux One Take:
    Crux Files:
    Crux BTS:

  • J&J vaccine much less effective against delta variant: New study

    1:26

    An NYU lab study suggests that one dose of the Johnson & Johnson vaccine is significantly less effective against the delta variant. The study confirms that Moderna and Pfizer's covid vaccines are still effective against the delta strain. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Intensive-care unit and lung doctor Dr. Vin Gupta told CNBC that he’s already encouraging patients who received the single-shot Johnson & Johnson Covid vaccine to get a Pfizer or Moderna booster shot amid the dramatic increase in delta variant cases across the U.S.

    Gupta, a professor at the University of Washington’s Institute for Health Metrics and Evaluation, told “The News with Shepard Smith” that “AstraZeneca, when combined with a Pfizer or Moderna booster, is showing tremendous levels of protection against delta, in terms of the antibody levels that are generated in patients.”

    “I do think that those one-shot J&Jer’s should be given the opportunity, while we complete our clinical trial ... I’m already telling my patients to do it, if they can get access to it.”

    Gupta’s comments come on the heels of a new study from a lab at New York University Tuesday that raises serious questions about the effectiveness of J&J’s single-dose vaccine against the highly contagious delta variant. The NYU study is not yet peer reviewed, but found that the antibody levels in those who received the J&J shot may be low enough to be less protective.

    CNBC correspondent Meg Tirrell interviewed the lead author of the study, Dr. Ned Landau, who told her that the study suggests, “one should at least consider a second vaccination, a second shot” with the J&J vaccine, either of the same vaccine, or one from Pfizer or Moderna.

    J&J told CNBC that its own data showed the vaccine “generated strong, persistent activity against the delta variant and other highly prevalent variants.”

    The Centers for Disease Control and Prevention told CNBC that it stands by its statement earlier this month about boosters that “Americans who have been fully vaccinated do not need a booster at this time.”

    Gupta furthered the case for administering a booster shot when he told host Shepard Smith that his “definition of fully vaccinated is two doses of a vaccine.”

    Smith asked for clarification on whether Gupta considers the nearly 13 million Americans who received the J&J dose were actually fully vaccinated.

    “I think you’re protected, likely from the hospital and severe outcomes from say, the delta variant, based on what data we do have,” Gupta said. “I do not think you have the same level of protection to transmit the virus than somebody who received two doses of the vaccine like Pfizer or Moderna. I think that is pretty clear at this point.”

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • FDA Issues Warning About J&J Covid Vaccine

    5:29

    Jul.13 -- Dr. Amesh Adalja, Johns Hopkins Center for Health Security senior scholar, discusses the warning added to Johnson & Johnson’s Covid-19 vaccine and the potential need for a third vaccine booster dose. The Johns Hopkins Bloomberg School of Public Health is supported by Michael R. Bloomberg, founder of Bloomberg LP and Bloomberg Philanthropies.

  • How J&J COVID-19 Vaccine Works, Animation

    1:41

    Johnson & Johnson’s COVID-19 Vaccine, How it works. Mechanism of JNJ coronavirus vaccine (same as Oxford-AstraZeneca vaccine).
    For comparison of different vaccines, as well as events of immune response, role of different immune cells (T-cells, B-cells, APC), see this video:
    Johnson & Johnson COVID-19 Vaccine is a viral vector vaccine. It can also be classified as DNA vaccine or recombinant vaccines. It uses a modified adenovirus as a vehicle to deliver the coronavirus DNA. The adenoviral genome is modified to remove adenoviral genes, so it can no longer replicate or cause disease. The gene coding for coronavirus (SARS-CoV2) spike gene is then added. After being injected, the adenovirus vector delivers the coronavirus DNA to the nucleus of antigen-presenting cells (APCs). The DNA is transcribed into mRNA, which exits to the cytoplasm, where it is translated into coronavirus spike protein. This protein is then cut into pieces and presented on the surface of APC as antigens for the immune system to detect. APCs move to the nearest lymph node, where they present the antigen to T-helper cells, which play central role in immune response. Helper T-cells activate cytotoxic T-cells, leading to cell-mediated immunity, and induce B-cells to produce antibodies, resulting in antibody-mediated immunity. Both of these branches produce long-lived memory cells that will respond immediately upon viral infection.
    This video is available for instant download licensing here:
    ©Alila Medical Media. All rights reserved.
    Support us on Patreon and get early access to videos and free image downloads: patreon.com/AlilaMedicalMedia
    All images/videos by Alila Medical Media are for information purposes ONLY and are NOT intended to replace professional medical advice, diagnosis or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.

  • Johnson & Johnson COVID-19 Vaccine: Effectiveness and Differences Between Vaccines

    6:27

    Kemi Olatunji, Pharm.D , Director of Pharmacy Services at Riverside Regional Medical Center, explains how the new Johnson and Johnson COVID-19 vaccine works and answers common questions, including why it's different from other coronavirus vaccines, how side effects compare to Pfizer and Moderna vaccines and more.

    For the latest information and resources on COVID-19, visit riversideonline.com/covid_19

  • Johnson & Johnson COVID-19 Vaccine

    16:48

    Dr. Dana Mazo discusses the Johnson & Johnson COVID-19 vaccine.

  • US pause Janssen vaccine

    20:50

    Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine





    Cerebral venous sinus thrombosis, together with low platelets

    Some sort of immune response

    6 cases from 6.8 million doses

    Look out for, severe headache, abdominal pain, leg pain or shortness of breath within three weeks of vaccination

    Paul A.Offit, vaccine specialist, Children’s Hospital of Philadelphia

    I think it’s the prudent thing to do

    I think it’s real — this is a rare, but real association

    Advisory Committee on Immunization Practices (ACIP), meets today

    EMA also investigating, delaying European rollout

    Janet Woodcock, acting commissioner, Food and Drug Administration

    One reason for the pause, health professionals must know not to use heparin

    All six cases in the US, occurred among women, 18 to 48

    6 – 13 days after vaccination

    Of the 6, 1 death and 1 critical

    Of the 6, 2 discharged

    The person in critical condition was (reportedly) treated with heparin

    Peter Marks, director of the FDA's centre for biologics evaluation and research

    hesitate to call it a class effect related to adenovirus vector vaccines

    It's plainly obvious to us already that what we're seeing with the Jansen vaccines looks very similar to what is being seen with the AstraZeneca vaccine

    AstraZeneca, chimpanzee adenoviral vector

    Janssen, human adenoviral vector vaccine

    I can't make some broad statement yet, but obviously they are from the same general class of viral vectors

    Scale of the problem

    100 million doses to US end of May

    can produce 1 billion doses globally by the end of the year

    has agreed to sell 500 million doses to developing nations via Covax purchasing agreement

    agreed to sell up to 400 million to African countries

    Turkey



    Cases, + 59,187 = 3,962,000 million

    Deaths, + 273 = 34,455

    President Tayyip Erdogan, partial closures

    Ramadan started yesterday

    France

    Cases, + 39,113 = 5,100,000

    Deaths, + 324 (in hospital) = 99,480

    ITU = 5,952

    One month lockdown in place since the end of March

    France will suspend all flights to and from Brazil

    Sweden

    AZ, being given to over 65s

    J&J arriving this week

    Russia

    Manufacturing of Sputnik V, soon in India, (50 m per month) Serbia, Iran, Italy

    India

    India approved Sputnik V on Monday

    UK



    Surge PCR testing south London

    Lambeth and Wandsworth (population 656,000)

    Testing available for all, symptomatic or asymptomatic

    Live, work or travel through

    South Africa variant

    Eeek, E484K, seems to reduce AZ efficacy

    Still protects against severe disease

    Does not seem to out compete UK variant

    New formulation of AZ for third shot later this year

    Who are these guys?

    Vitamin D

  • Dr. Sandra Fryhofer on the J&J Janssen COVID-19 vaccine pause | COVID-19 Update for April 15, 2021

    10:47

    Dr. Sandra Fryhofer—the AMA liaison to the CDC’s Advisory Committee on Immunization Practices and the AMA’s representative on the COVID-19 vaccine work group—provides a quick and comprehensive look at the emerging details regarding the J&J/ Janssen COVID-19 vaccine, and what physicians need to know about the vaccine pause.

    Stay up to date on the latest information about the pandemic:
    Visit the COVID-19 Daily Video Updates page for more videos in this series:

  • I Got Vaccinated. My Experience With The Janssen Johnson & Johnson 1 Shot COVID Vaccine

    10:01

    I Got Vaccinated. My Experience With The Janssen Johnson & Johnson 1 Shot COVID Vaccine

    NOT AN AMAZON PRIME MEMBER? JOIN HERE:
    JOIN MY PATREON!:

    ???? Camera stuff I use for my videos -
    Sony ZV-1 Camera:
    Ulanzi Wide Adapter for vlogging:
    Nebula tabletop tripod (great for vlogging!):
    Peak Designs Carbon Fiber Tripod:
    Sennheiser AVX wireless lav mic system:
    Boya MM-1 Mic:

    Free month of Roon:
    TorGuard is the VPN I use and recommend. Use code TT50 for 50% off:

    [As an affiliate, I may earn from purchases made using the links here]

    ????GET NOTIFIED: SUB!

    INSTAGRAM:
    TWITTER:

    #covidvaccine #experience #whattoexpect

  • Janssen - Johnson & Johnson Coivd-19 Vaccine

    3:24

    For more health information visit health.mo.gov
    For news about the State of Missouri visit mo.gov

  • Infectious Disease Doctor Calls J&J COVID-19 Vaccine “A Game Changer”

    2:50

    #uvahealth #covidvaccine
    UVA Critical Care and Infectious Disease physician, Taison Bell, says he was excited about the availability of the one-dose COVID-19 vaccine from J&J. He explains how the vaccine works and addresses concerns that people may have about the vaccine’s efficacy numbers.

    Find out more about the vaccine at:

    Transcript

    TAISON BELL, MD: My name is Taison Bell. I'm a critical care and infectious disease physician at the University of Virginia.

    I was personally excited to see the Johnson & Johnson vaccine news, and then trial that came out and I expected it to be authorized by the FDA. It has a couple of advantages. So the first one is that it uses a slightly different platform. So instead of the messenger RNA that Moderna and Pfizer uses, this one uses a viral vector and adenovirus. And that's just a virus that causes the common cold, but it's modified so that it doesn't actually cause you to get sick. What it does do is allows a piece of DNA, so in opposed to RNA. It's a different vehicle, but the destination is the same.

    It’s teaching your body how to make the spike protein so that your body can make antibodies to it. And then later, if you get exposed to the coronavirus, you can rally the troops, get it out of there and prevent you from getting sick. So it works. The end game is the exact same.

    Now what I've gotten a lot of questions about is, well, what do I make of these different efficacy numbers? So, the 66% efficacy versus the 94-95%. Now you could sit back, and say, if I got the Johnson & Johnson, why would I want to take that? If I've got the Pfizer, Moderna, that I could just wait a little bit longer for? Now, this is what I want to talk about. You know, what does efficacy mean?

    If we dig down deeper into that data for Johnson & Johnson, and we think, you know, what are the things that we care about. People going to the hospital for COVID-19 with severe disease, people dying from COVID-19 from severe disease. They actually stack up pretty well against each other. So the Johnson & Johnson vaccine, for the 28 day period, before it takes for the vaccine to take full effect, from that point on, there were no people who went to the hospital with COVID-19. Absolutely zero. People who died from COVID-19, absolutely zero.

    So that 66% efficacy number is a little misleading because what this also is, is a life-saving vaccine. Now to put this in context, our flu vaccine is between 40 to 60% of efficacy. I take the flu shot every year, and it's something that we use as something to protect us from another deadly pandemic that happens on a global scale every single year. The Johnson & Johnson vaccine actually has higher efficacy than the influenza vaccine. And then when you combine that with the fact that if you look at people who've had the most severe illness and see that, you know, it really protects you against that with a one-dose regimen, that's easy to distribute, much easier to distribute. I think it's a game changer and personally for myself or my family members, if I had access to either one of them, that's the one that's going in my arm as quickly as possible, because I want the thing that's going to protect me from having a severe disease, from dying of COVID-19. And all three of these vaccines will do that.

  • Live Q&A on Janssen #COVID19 vaccine with @Kate_L_OBrien and Dr Alejandro Cravioto. #AskWHO

    46:36

  • Concerns Over Johnson & Johnson Vaccine

    1:54

    The FDA and the CDC have recommended pausing the use of Johnson & Johnson vaccine after reports of rare blood clots. What symptoms should you look for if you receive this vaccine? NBC Bay Area’s Raj Mathai talks to experts about concerns over this specific vaccine.

    Stay connected:
    Follow us on Twitter:
    Like us on Facebook:
    Follow us on Instagram:
    Add us on Snapchat @NBCBayArea

    Catch up on all the day's news:

    Download our app:
    On iOS:
    On Android:

  • US Calls For Pause On Johnson & Johnson Vaccine | TODAY

    5:03

    The New York Times is reporting that federal officials will call for an immediate pause in the use of Johnson & Johnson’s single-dose coronavirus vaccine due to incidents of blood clotting. “There are very, very rare events,” NBC medical contributor Dr. Natalie Azar tells TODAY, and predicts the vaccine “will continue to be a very powerful tool in the arsenal” against the coronavirus.
    » Watch TODAY All Day:
    » Subscribe to TODAY:
    » Watch the latest from TODAY:

    About: TODAY brings you the latest headlines and expert tips on money, health and parenting. We wake up every morning to give you and your family all you need to start your day. If it matters to you, it matters to us. We are in the people business. Subscribe to our channel for exclusive TODAY archival footage & our original web series.

    Connect with TODAY Online!
    Visit TODAY's Website:
    Find TODAY on Facebook:
    Follow TODAY on Twitter:
    Follow TODAY on Instagram:
    Follow TODAY on Pinterest:

    #DrNatalieAzar #Coronavirus #TodayShow

    US Calls For Pause On Johnson & Johnson Vaccine | TODAY

  • The latest on the Johnson & Johnson COVID-19 vaccine

    2:32

    Dr. Jen Ashton has what you need to know about the pause in the Johnson & Johnson vaccine distribution.

  • Johnson & Johnsons Janssen Vaccine Approved For Emergency Use In India | Republic TV

    7:21

    Johnson & Johnson's Janssen Vaccine Approved For Emergency Use In India

    #Johnson&Johnson #Janssen #RepublicTV

    Republic Bangla is now LIVE ►

    Subscribe to Republic Bangla and press THE BELL ICON to never miss any updates ►

    Also subscribe to Republic TV & press THE BELL ICON to be updated with the latest news ►

    Official Website -

    Republic TV is India's no.1 English news channel since its launch. It is your one-stop destination for all the live news updates from India and around the world. Republic TV makes news accessible for you at your convenience, at all times and across devices. At Republic we keep you updated with up-to-the-minute news on politics, sports, entertainment, lifestyle, gadgets and much more.

    We believe in Breaking the story and Breaking the Silence. But most importantly, for us ‘You Are Republic, We Are Your Voice.’

    Also, Watch ►
    Republic TV Live News Updates ►
    The Debate With Arnab Goswami ►
    Biggest Story Tonight ►
    Burning Question Debates ►
    Patriot With Major Gaurav Arya ►
    Exclusive Sunday Debate With Arnab Goswami ►

    You can stay connected with Republic TV on -

    Facebook -
    Follow us on Twitter -
    Official Website -

  • What You Need to Know About the Johnson & Johnson Vaccine

    2:41

    Aisha Langford, MPH, PhD, assistant professor in NYU Langone’s Department of Population Health, explains how the Johnson & Johnson vaccine works and the ways in which it is as effective as the Pfizer and Moderna vaccines.

  • Janssen applies for emergency use authorization for J&J COVID-19 vaccine in PH | ANC

    5:50

    Dateline Philippines: Johnson & Johnson's COVID-19 vaccine is now up for review in the Philippines after J&J's pharmaceutical firm Janssen applied for emergency use authorization last week.

    For more ANC interviews, click the link below:


    For more COVID-19 videos, click the link below:


    For more Rundown videos, click the link below:


    Subscribe to the ANC Youtube channel!


    Visit our website at
    Facebook:
    Twitter:

    #ANCNews
    #ANCHighlights
    #ANCInterviews

  • Expecting data on J&J vaccines effectiveness against the delta variant

    2:36

    CNBC's Meg Tirrell on the need for masks and booster shots to battle the new Covid delta variant. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Moderna said Tuesday its Covid-19 vaccine showed promise in a lab setting against coronavirus variants, including the highly contagious delta variant first identified in India.

    The two-dose mRNA vaccine produced neutralizing antibodies against delta as well as beta and eta, variants first found in South Africa and Nigeria, respectively, according to Moderna.

    The company said the results were based on the blood serum of eight participants one week after they received the second dose of the vaccine. The data hasn’t yet been peer-reviewed. The results, while promising, may not reflect how the vaccines actually perform in real-world scenarios against the variants.

    Shares of Moderna jumped more than 6% in intraday trading after it announced the lab results.

    “We remain committed to studying emerging variants, generating data and sharing it as it becomes available,” Moderna CEO Stephane Bancel said in a press release. “These new data are encouraging and reinforce our belief that the Moderna COVID-19 Vaccine should remain protective against newly detected variants.”

    Moderna’s update comes days after World Health Organization officials urged fully vaccinated people to continue to wear masks, social distance and practice other pandemic safety measures as delta spreads rapidly across the globe.

    It also comes the same day Moderna said its vaccine was authorized for use in India, where the delta variant is thought to be behind the large outbreak there.

    Delta, now in at least 92 countries, including the United States, is expected to become the dominant variant of the disease worldwide. In the U.S., the prevalence of the strain is doubling about every two weeks.

    WHO officials said Friday they are asking fully vaccinated people to continue to “play it safe” because a large portion of the world remains unvaccinated and highly contagious variants, like delta, are spreading in many countries, spurring outbreaks.

    The comments were a departure from the Centers for Disease Control and Prevention, which has said fully vaccinated Americans can go maskless in most settings.

    “People cannot feel safe just because they had the two doses. They still need to protect themselves,” Dr. Mariangela Simao, WHO assistant director-general for access to medicines and health products, said during a news briefing.

    Authorized vaccines from Moderna, Pfizer-BioNTech and Johnson & Johnson have demonstrated to be highly effective in preventing Covid, especially against severe disease and death.

    Some variants, including delta, have shown to make the vaccines slightly less effective and WHO officials said they worry vaccinated individuals could become part of transmission chains.

    The Wall Street Journal reported Friday that about half of adults infected in an outbreak of the delta variant in Israel were fully vaccinated with the Pfizer vaccine, prompting the government there to reimpose an indoor mask requirement and other measures.

    In the U.S., President Joe Biden warned that unvaccinated people are especially at risk of becoming infected with delta.

    He said Covid deaths nationwide will continue to rise due to the spread of the “dangerous” variant, calling it a “serious concern.”

    “Six hundred thousand-plus Americans have died, and with this delta variant you know there’s going to be others as well. You know it’s going to happen. We’ve got to get young people vaccinated,” Biden said Thursday at a community center in Raleigh, North Carolina.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:



    #CNBC
    #CNBCTV

  • Johnson & Johnson vaccine shows promise against Delta variant, plus COVID-19 back-to-school concerns

    1:59

    #Johnson&Johnson #Deltavariant #coronavirus #backtoschool
    Yahoo Finance's Anjalee Khemlani reports the latest news on the Delta variant and the Johnson&Johnson vaccine, Anjalee also spoke with Dr. Paul Offit, Children’s Hospital of Philadelphia (CHOP) director of the Vaccine Education Center about concerns regarding COVID-19 as children get ready to return to school in the fall.
    Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube:


    Subscribe to Yahoo Finance:

    About Yahoo Finance:
    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

    Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
    To learn more about Yahoo Finance Plus please visit:

    Connect with Yahoo Finance:
    Get the latest news:
    Find Yahoo Finance on Facebook:
    Follow Yahoo Finance on Twitter:
    Follow Yahoo Finance on Instagram:
    Follow Cashay.com
    Follow Yahoo Finance Premium on Twitter:

  • Johnson & Johnson’s COVID-19 Vaccine Timeline, Partnerships & The Road Ahead | Johnson & Johnson

    1:59

    “This pandemic is something we have to combat all together.” — Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.

    Johnson & Johnson is honored to collaborate on a historic partnership with @Merck and the Biden administration to ramp up production and manufacturing of the Janssen COVID-19 Vaccine and help expedite our collective return to normalcy. Watch as we look back on the company’s vaccine development timeline from the start of the coronavirus pandemic to present day and beyond.

    Vaccine is authorized for emergency use and not approved or licensed by the U.S. FDA Read more:

    Subscribe to J&J on YouTube and keep up-to-date with our latest videos:

    Connect with Johnson & Johnson on social media:
    J&J on Facebook:
    J&J News on Twitter:
    J&J on LinkedIn:

    Find updates and news about J&J, including the company’s ongoing work on a COVID-19 vaccine, here:

  • Covid: Johnson & Johnson single-shot vaccine approved for use in UK | ITV News

    1:53

    The single-shot Johnson & Johnson vaccine has been approved for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).

    Trials have shown the jab has been shown to be 67% effective overall at preventing moderate to severe Covid-19, and is thought to be 85% effective in preventing severe disease or admission to hospital.

    The jab has been produced by Janssen, the Belgian-based pharmaceutical arm of the US health conglomerate Johnson & Johnson (J&J).

    The government has secured 20 million doses for all of the UK and it is expected to be rolled out towards to end of this year.

    • Subscribe to ITV News on YouTube:
    • Get breaking news and more stories at

    Follow ITV News on Facebook:
    Follow ITV News on Twitter:
    Follow ITV News on Instagram:

  • What Clinicians Should Know About Johnson & Johnson Janssen COVID-19 Vaccine

    59:20

    This COCA Call will give clinicians an overview of the J&J Janssen COVID-19 vaccine. Clinicians will learn about vaccine characteristics and administration, vaccinating special populations, and contraindications. They will also get answers to a number of clinical questions CDC has received about this new vaccine.

    This video can also be viewed at

  • Johnson And Johnson Vaccine: Everything You Need To Know

    47:16

    The Johnson and Johnson Vaccine, also known as the Janssen Vaccine or JNJ-784336735 or Ad.26.COV2.S, is the most recent vaccine to receive emergency use authorization in the United States (along with the Moderna and Pfizer Vaccines). This vaccine though is distinctly different than the mRNA vaccine technology that Pfizer and Moderna utilize. Check out the video for everything you should know about this new COVID-19 vaccine!

    We talk about the different nomenclature used and why, storage and dosing, and vaccine ingredients in detail. We will then dive into how the vaccine works and the type of immune response it prompts. We dive into the Phase 1, 2, and 3 Trials (ENSEMBLE) including the immunogenicity (antibody and T cell memory) and adverse events. Lastly, we talk about the vaccine efficacy, timeline to efficacy, efficacy against the different variants, prevention of hospitalization and death, and preventing of asymptomatic infection. Check out the video for all these details and more!

    Links to sources and trials used:






    Playlist on all things COVID-19 Vaccines:


    Playlist on all things COVID-19 Viral Variants:


    If you enjoy the content and feel inclined, here are some ways in which you can support us! Funds will go towards purchasing better equipment/software, dedicating more time to the channel, and continuing to strive towards taking this channel to the next level!

    PayPal:


    Buy Us A Coffee:
    A cool site where you can donate a few dollars to a Creator of your choosing as a tip!


    YouTube Membership tab:
    It has a “Join” button at the top right corner of our Channel’s home page. We appreciate you!

    Become a WBDR Patreon Patron:
    Get exclusive perks, merchandise, and more!


    We love to get involved in the #FOAMed world through Twitter as well. Come check us out, we would love to hear from you! @WhiteBoardDoct1


    There will be a running series of videos using the most up to date information on COVID-19, but this is an evolving field and new videos may come out that contradict that previous information. That is okay and is the nature of a fast paced and evolving clinical scenario. Stick with us as we work to unveil the intricacies of COVID-19, it's clinical significance, and the societal implications. ***This is strictly educational and not to be mistaken as clinical recommendations, please verify all information with accepted guidelines and practice patterns.***

    DISCLAIMER
    THIS VIDEO DOES NOT PROVIDE MEDICAL ADVICE. The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read, watched, or listened to on this video, or any other videos, reports, texts tweets or other sources.

  • Johnson & Johnson Covid-19 vaccine study paused due to unexplained illness in participant

    3:08

    The study of Johnson & Johnson's Covid-19 vaccine has been paused due to an unexplained illness in a study participant. CNBC's Squawk Box crew discusses. For access to live and exclusive video from CNBC subscribe to CNBC PRO:

    Johnson & Johnson’s late-stage coronavirus vaccine was paused after a participant reported an “adverse event” about 36 hours earlier, the company’s chief financial officer said Tuesday.

    The pause will allow the data and safety monitoring board to thoroughly investigate the unexplained illness, CFO Joseph Wolk said in an interview on CNBC’s “Squawk Box.”

    “We’re letting safety protocol follow proper procedure here,” he said, adding that pauses in trials are “not uncommon.”

    “What it should also do is reassure the public that every scientific, medical and ethical standard is being applied here,” Wolk added.

    J&J confirmed to STAT News on Monday that a “pausing rule” in the 60,000-patient clinical trial had been met, but declined to provide further details on the patient.

    “We must respect this participant’s privacy,” the company said in a statement late Monday. “We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”

    J&J began its phase three trial testing of its potential coronavirus vaccine last month, becoming the fourth drugmaker backed by the Trump administration’s Covid-19 vaccine program Operation Warp Speed to enter late-stage testing.

    J&J has said it is using the same technologies it used to develop its experimental Ebola vaccine. It involves combing genetic material from the coronavirus with a modified adenovirus that is known to cause common colds in humans. Preclinical studies have shown the potential vaccine can generate a promising response in nonhuman primates and hamsters.

    It’s unclear if the participant in the J&J trial received the vaccine or a placebo.

    Dr. Mathai Mammen, global head of Janssen research and development at J&J, told investors on a conference call later Tuesday that the company still knows “very little information,” including if the patient received the vaccine or the placebo. J&J was informed of the illness Sunday evening and released a statement the following day, he said. Preliminary information has been sent to the data and safety monitoring board for review, he added.

    “It’ll be a few days at minimum for the right information to be gathered,” he said.

    Dr. Ezekiel Emanuel, a former health advisor in the Obama administration, said it would “raise serious questions” if the participant received the vaccine.

    “One adverse event is serious, especially when you’re considering a vaccine that you’re going to roll out to tens, hundreds of millions of people, maybe even billions,” he said on “Squawk Box.” “That’s the ultimate concern.”

    Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said the company has provided “no real information.” Because adverse events are kept confidential, he said, he’s not sure when the public will know more.

    The trial pause is likely to add to uncertainty about when a safe and effective vaccine will be ready.

    J&J isn’t the first frontrunner in the race for a vaccine to halt a late-stage trial due to an unexplained illness.

    AstraZeneca announced on Sept. 8 that its trial had been put on hold due to an unexplained illness in a patient in the United Kingdom. The patient is believed to have developed inflammation of the spinal cord, known as transverse myelitis. The trial has since resumed in the U.K. and other countries, but is still on hold in the United States.

    » Subscribe to CNBC TV:
    » Subscribe to CNBC:
    » Subscribe to CNBC Classic:

    Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

    The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

    Connect with CNBC News Online
    Get the latest news:
    Follow CNBC on LinkedIn:
    Follow CNBC News on Facebook:
    Follow CNBC News on Twitter:
    Follow CNBC News on Instagram:

    For info on the best credit cards go to CNBC Select:


    #CNBC
    #CNBCTV

  • Johnson & Johnson vaccine review follows blood clot cases | Coronavirus Vaccine |Latest English News

    1:55

    European drug regulators are undertaking review of rare blood clots in four people in the United States of America who have received Johnson & Johnson COVID-19 vaccine.

    #J&J #CoronavirusVaccine #EnglishNews

    About Channel:

    WION -The World is One News, examines global issues with in-depth analysis. We provide much more than the news of the day. Our aim to empower people to explore their world. With our Global headquarters in New Delhi, we bring you news on the hour, by the hour. We deliver information that is not biased. We are journalists who are neutral to the core and non-partisan when it comes to the politics of the world. People are tired of biased reportage and we stand for a globalised united world. So for us the World is truly One.

    Please keep discussions on this channel clean and respectful and refrain from using racist or sexist slurs as well as personal insults.

    Subscribe to our channel at
    Check out our website:
    Connect with us on our social media handles:
    Facebook:
    Twitter:

    Follow us on Google News for latest updates

    Zee News:-
    Zee Bussiness:-
    DNA India:-
    WION:
    Zee News Apps :

  • Johnson & Johnson Vaccine arrives at Tufts MC

    1:38

    We are excited to now be providing the Johnson & Johnson (Janssen) vaccine at our COVID-19 vaccination site.

  • Why is the Johnson & Johnson vaccine just as effective as the Moderna and Pfizer vaccines?

    1:06

    Keith Armitage, MD, infectious disease physician and Medical Director, UH Roe Green Center for Travel Medicine & Global Health, discusses the important efficacy similarities between the Johnson & Johnson vaccine and the Moderna/Pfizer vaccines.

  • Homeless receive Johnson & Johnson Janssen COVID-19 Vaccine

    1:44

    Thursday, March 4, 2021 - Clients at The Rescue Mission of Trenton are among the first to receive the new Johnson & Johnson Janssen COVID-19 Vaccine, distributed by medical professionals from the Henry J. Austin Health Center. Two men, Desmond Gilchrist and Pedro Carmenate, speak of their experiences. Michael Mancuso | NJ Advance Media for NJ.com

Shares

x

Check Also

Menu